Article
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
The New England journal of medicine - 3 Sept 2020
Paik Paul K, Felip Enriqueta, Veillon Remi, Sakai Hiroshi, Cortot Alexis B, Garassino Marina C, Mazieres Julien, Viteri Santiago, Senellart Helene, Van Meerbeeck Jan, Raskin Jo, Reinmuth Niels, Conte Pierfranco, Kowalski Dariusz, Cho Byoung Chul, Patel Jyoti D, Horn Leora, Griesinger Frank, Han Ji-Youn, Kim Young-Chul, Chang Gee-Chen, Tsai Chen-Liang, Yang James C-H, Chen Yuh-Min, Smit Egbert F, van der Wekken Anthonie J, Kato Terufumi, Juraeva Dilafruz, Stroh Christopher, Bruns Rolf, Straub Josef, Johne Andreas, Scheele Jürgen, Heymach John V, Le Xiuning
Abstract excerpt
BACKGROUND: A splice-site mutation that results in a loss of transcription of exon 14 in the oncogenic driver MET occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: In this open-label, phase 2 study, we administered tepotinib (at a dose of 500 mg) once daily in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.